Virtual Reality Support for Newly Diagnosed Black Men with Prostate Cancer

This study is testing a virtual reality (VR) assistant called ViRA to help Black men newly diagnosed with prostate cancer. Prostate cancer is a serious health concern for Black men, who are diagnosed more often than White men. The ViRA app aims to provide support, help with social needs (like finding resources), and offer emotional and psychological support. Researchers want to see if ViRA can reduce emotional distress and improve how patients feel overall. You may be able to join if you are an African American/Black man, recently diagnosed with prostate cancer (within two months), and are a patient at a participating clinic. The study plans to enroll 200 participants.

Study design
This study is an interventional trial that will enroll 200 men. Participants will be randomly assigned to one of two groups: one receiving standard care and then the ViRA app later, or one receiving the ViRA app right away.
What's involved
Participants will receive either standard care or access to the ViRA application on a VR headset, smartphone, iPad, or computer. The ViRA app will present screening questions and recommend personalized interventions.
Compensation
Not stated in the trial record.
Follow-up
The study will track your use of ViRA at baseline, 1 month, 3 months, 6 months, 9 months, and 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07126548

A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men

Not Yet Recruiting
NAAll AgesInterventionalSupportive care
Mayo Clinic
~200 participants
Updated 2026-04-20 on ClinicalTrials.gov
What's tested:Best PracticeDiscussionSurvey AdministrationVirtual Reality

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Reach - enrollment
Measured over Baseline
+3 more outcomes measured
Prostate Carcinoma
1 sites across 1 states
Florida1
  • Folakemi T. Odedina, PhD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

African American/Black male
Diagnosed with CaP within two months
Be a patient at a participating clinic or affiliates with one of our community sites
Consent to participating in the study

Exclusion

Do not speak or understand English
Unable to read or write
  • Reach - enrollmentBaseline

    Reach of the point of prostate cancer diagnosis (PPCD) virtual reality assistant (ViRA) will be measured by the number of AA/BM who enroll in the study when offered.

  • Reach - acceptance of ViRABaseline

    Reach of the PPCD ViRA will be measured by the % of AA/BM who accept the ViRA when offered.

  • Reach - initiation of ViRABaseline, 1 month, 3 months, 6 months, 9 months, 12 months

    Reach of the PPCD ViRA will be measured by the number of AA/BM who initiate the ViRA at the clinic vs. home vs. community setting.

  • Utilization of the PPCD ViRABaseline, 1 month, 3 months, 6 months, 9 months, 12 months

    Will be measured by total # of AA/BM who used the Vira at least once a week.